Solid-state characterization and dissolution properties of bicalutamide-β-cyclodextrin inclusion complex

Pharmazie

Volumn 63, Issue 4, 2008, Pages 282-285

  Patil, A L ^a   Pore, Y V ^a   Kuchekar, B S ^a   Late, S G ^b  

^a Government College of Pharmacy   (India)

^b MERCER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CYCLODEXTRIN; BICALUTAMIDE;

ARTICLE; COMPLEX FORMATION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG SOLUBILITY; DRUG STABILITY; INFRARED SPECTROSCOPY; SOLID STATE; X RAY POWDER DIFFRACTION;

ANDROGEN ANTAGONISTS; ANILIDES; BETA-CYCLODEXTRINS; CALORIMETRY, DIFFERENTIAL SCANNING; CRYSTALLOGRAPHY, X-RAY; DRUG COMPOUNDING; NITRILES; SOLUBILITY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; TOSYL COMPOUNDS;

EID: 42149135420     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2008.7260     Document Type: Article

References (16)

1. Cockshot ID, Oliver SD, Young JJ, Cooper KJ, Jones DC (1997) The effect of food on the pharmacokinetics of the bicalutamide (Casodex) enantiomers. Biopharm Drug Dispos 18: 499-507.
2. Cockshot ID (2004) Bicalutamide clinical pharmacokinetics & metabolism. Clin Pharmacokinet 43: 855-878.
3. Fradet Y (2004) Bicalutamide (Casodex) in the treatment of prostate cancer. Expert Rev Anticancer Ther 4: 37-48.
4. Furr BJA, Blackledge GRP, Cockshot ID (1996). Casodex: preclinical and clinical studies. In: Pasqualini JR, Katzenellenbogen BS (ed.) Hormone Dependent Cancer, Marcel Dekker Inc, NewYork, p. 397-424.
5. Fuzheng R, Qiufang J, Yanhui T, Yongjia S, Jialei C, Feng G, Jingbin C (2006) Characteristics of bicalutamide solid dispersions and improvement of the dissolution. Drug Dev Ind Pharm 32: 967-972.
6. Higuchi T, Connors KA (1965) Phase-solubility techniques. Adv Anal Chem Instr 4: 117-212.
7. Longxiao L, Suyan Z (2006) Preparation and characterization of inclusion complexes of prazosin hydrochloride with β-cyclodextrin and hydroxypropyl-β-cyclodextrin. J Pharm Biomed Anal 40: 122-127.
8. Mukherjee A, Kirkovsky L, Yao XT, Yates CR, Dalton JT (1996) Enantioselective binding of casodex to the androgen receptor. Xenobiotica 26: 117-122.
9. Mukne AP, Nagarsenker MS (2004) Triamterene-β-cyclodextrin systems: preparation, characterization and in vivo evaluation. AAPS PharmSciTech 5: E19.
10. Proudfoot S (1991) Factors affecting bioavailability: factors influencing drug absorption from gastrointestinal tract. In: Aulton ME (ed.) Pharmaceutics: The Science of Dosage Form Design, Edinburgh: Churchil Livingstone, p. 135-173.
11. Reddy MN, Rehana T, Ramakrishna S, Chowdary KPR, Diwan PV (2004) β-cyclodextrin complexes of celecoxib: molecular-modeling, characterization, and dissolution studies. AAPS PharmSci 6: E7.
12. Ryan JA (1986) Compressed pellet x-ray diffraction monitoring for optimisation of crystallinity in lyophilised solids: imipenem: cilastatin sodium case. J Pharm Sci 75: 805-807.
13. Tucker H, Chesterton GJ (1988) Resolution of the nonsteroidal antiandrogen 4′-cyano-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl- 3′-(trifluromethyl)-propionanilide and the determination of the absolute configuration of the active enantiomer. J Med Chem 31: 85-87.
14. U.S. Food and Drug Administration. Dissolution methods for drug products Website. Available at: http://www.accessdata.fda.gov/scripts/cder/ dissolution/dsp_SearchResults_Dissolutions.cfm?PrintAll=1. Accessed November 30, 2006.
15. Vega DR, Polla G, Martinez A, Mendioroz E, Reinoso M (2006) Conformational polymorphism in bicalutamide. Int J Pharm 328: 112-118.
16. Xianhong W, Fei T, Zhijun J, Ziuyang L (2004) Preparation and study the 1:2 inclusion complex of carvedilol with β-cyclodextrin. J Pharm Biomed Anal 34: 517-523.